However, solid cancers including lung cancer lack such activating somatic mutations.23, 41 Nevertheless, clinical trials for lung AC patients were launched using JAK inhibitors ruxolitinib, in particular for patients with activating EGFR‐mutations upstream of JAK1 and JAK2 (NCT02155465, NCT02145637, NCT02917993, NCT03450330). This evidence concerns the gene JAK2 and lung carcinoma.